山河药辅: 董事会决议公告

Core Points - The company held its seventh meeting of the sixth board of directors on August 26, 2025, with all eight directors present, confirming compliance with relevant laws and regulations [1][2]. - The board approved the 2025 semi-annual report, affirming that the report accurately reflects the company's actual situation without any false statements or omissions [1][2]. - The board also approved a special report on the management and use of raised funds for the first half of 2025, confirming compliance with regulatory requirements [2]. Summary by Sections - Meeting Details - The meeting was attended by all eight directors, and the notice was sent out on August 17, 2025 [1]. - The meeting was chaired by Mr. Yin Zhenglong [1]. - Approval of Semi-Annual Report - The board reviewed and approved the 2025 semi-annual report, ensuring its authenticity and completeness [1][2]. - Voting results showed unanimous support with 8 votes in favor [2]. - Approval of Fund Management Report - The board approved a special report on the management and use of raised funds, confirming adherence to relevant regulations [2]. - This report was also reviewed and approved by the audit committee prior to the board meeting [2].